Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Seeking Clues to ANI (ANIP) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
The upcoming report from ANI Pharmaceuticals (ANIP - Free Report) is expected to reveal quarterly earnings of $0.93 per share, indicating a decline of 27.3% compared to the year-ago period. Analysts forecast revenues of $127.62 million, representing an increase of 9.5% year over year.
The current level reflects a downward revision of 1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain ANI metrics that are commonly tracked and forecasted by Wall Street analysts.
Based on the collective assessment of analysts, 'Net Revenues- Generic pharmaceutical products' should arrive at $69.45 million. The estimate indicates a year-over-year change of +9.7%.
The consensus estimate for 'Net Revenues- Rare disease pharmaceutical products' stands at $41.82 million. The estimate points to a change of +72.1% from the year-ago quarter.
Analysts expect 'Net Revenues- Established brand pharmaceutical products, royalties, and other pharmaceutical services' to come in at $15.82 million. The estimate suggests a change of -45.3% year over year.
View all Key Company Metrics for ANI here>>>
Over the past month, ANI shares have recorded returns of -0.7% versus the Zacks S&P 500 composite's -2.9% change. Based on its Zacks Rank #3 (Hold), ANIP will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>